

**MaxCyte Announces Closing of Offering and Resulting Total Voting Rights**

**This announcement contains inside information**

**GAITHERSBURG, MD, August 3, 2021** - MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT, MXCN) ("MaxCyte" or the "Company"), a leading provider of cell-engineering platform technologies, today announced the closing of its offering of 15,525,000 shares of common stock (the "Offering") at a price of US \$13.00 per share, for aggregate gross proceeds of approximately US \$201,825,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by MaxCyte. The shares of common stock were offered in a registered public offering in the United States.

MaxCyte's common stock began trading on the Nasdaq Global Select Market under the symbol "MXCT" on July 30, 2021. MaxCyte's common stock will continue to be admitted to trading on the AIM market of London Stock Exchange plc ("AIM") under the symbols "MXCT" and "MXCN." Application has been made for the shares of common stock issued in the Offering to be admitted to trading on AIM and it is expected that admission will become effective and dealings in the shares of common stock will commence at 8:00 a.m. (BST) on 4 August, 2021.

Cowen, Stifel and William Blair acted as joint book-running managers for the Offering and as representatives of the underwriters for the Offering. BTIG and Stephens Inc. acted as co-managers of the Offering.

Following the closing of the Offering, the issued share capital of the Company is 100,259,803 shares of common stock, including the shares issued in the Offering and 15,458 shares issued in July 2021 pursuant to the exercise of options. This figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the applicable Securities and Exchange Commission disclosure rules or under the Disclosure Guidance and Transparency Rules published by the Financial Conduct Authority. The number of unrestricted shares of common stock trading under the symbol "MXCT" is 99,929,803 and the number of restricted shares of common stock trading under the symbol "MXCN" is 330,000.

A registration statement, including a prospectus, relating to these securities has been filed by MaxCyte and was declared effective by the Securities and Exchange Commission on 29 July 2021. Copies of the registration statement can be accessed through the SEC's website at [www.sec.gov](http://www.sec.gov). The Offering was made only by means of a prospectus. Copies of the final prospectus relating to and describing the terms of the Offering may be obtained from the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, USA, Attn: Prospectus Department, by telephone at +1 (833) 297-2926 or by email at [PostSaleManualRequests@broadridge.com](mailto:PostSaleManualRequests@broadridge.com); Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, USA, by telephone at +1 (415) 364-2720 or by email at [syndprospectus@stifel.com](mailto:syndprospectus@stifel.com); or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, USA, by telephone at +1 (800) 621-0687 or by email at [prospectus@williamblair.com](mailto:prospectus@williamblair.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.

**About MaxCyte**

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialisation of next-generation cell therapies. The company's existing customer base ranges from large biopharmaceutical companies -- including 20 of the top 25 pharmaceutical companies based on 2020 global revenue -- to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers that allow for more than 75 clinical programmes. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

**MaxCyte Contacts:**

<p><b>MaxCyte Inc.</b> Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer</p>	+1 301-944-1660	
<p><i>Nominated Adviser and Joint Corporate Broker</i> Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden</p>	+44 (0)20 7886 2500	
<p><i>Joint Corporate Broker</i> <b>Numis Securities Limited</b> James Black / Duncan Monteith / Matthew O'Dowd</p>	+44 (0)20 7260 1000	
<p><i>Joint Corporate Broker</i> <b>Stifel Nicolaus Europe Limited</b> Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiya Corporate Broking Nick Adams</p>	+44 (0)20 7710 7600	
<p><i>UK IR Adviser</i> <b>Consilium Strategic Communications</b> Mary-Jane Elliott Chris Welsh</p>	+44 (0)203 709 5700 <a href="mailto:maxcyte@consilium-comms.com">maxcyte@consilium-comms.com</a>	
<p><i>US IR Adviser</i> <b>Gilmartin Group</b> David Deuchler, CFA</p>	+1 415-937-5400 <a href="mailto:ir@maxcyte.com">ir@maxcyte.com</a>	

**Forward-Looking Statements**

Certain statements made in this press release are forward-looking statements including with respect to the admission of the shares of common stock to trading on AIM. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including if the shares of common stock are not admitted to trading on AIM or admission is delayed or if there are adverse market or economic conditions. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDKNBQOBKDFK